Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPLY-PNH: Oral LNP023 in PNH Patients with Residual Anemia on Anti-C5 Therapy
jRCT2051200132Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of Iptacopan in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Novartis. Primary endpoints: Sustained hemoglobin increase ≥2 g/dL without transfusion and Sustained hemoglobin ≥12 g/dL without transfusion. Started Mar 2021; status: completed.
02
Drugs
Iptacopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on jRCT2051200132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200132.